Unlike many biotech startups reliant on venture capital, Vivtex pursued a different path. By securing around 10 early pharma collaborations, the company generated a substantial stream of non-dilutive revenue, achieving profitability and financial independence far earlier than is typical.

Voyager CEO Al Sandrock views partnerships as more than just revenue. He emphasizes that strong scientific collaborations are invaluable because direct interaction between partner scientists accelerates learning and overall progress for both organizations. This intellectual cross-pollination is a key, often overlooked, benefit of partnering out platform technology.

Vivtex's early low profile was a strategic choice to mature its technology and precisely define its value to partners. This 'figuring it out' period allowed them to avoid making a premature public splash with offerings they might later have to retract, ensuring a stronger, more coherent market entry.

While scientific acumen is valuable, the most critical trait for a biotech CEO is perseverance. The role involves weathering constant challenges where everyone—the board, investors, employees—can seem to be against you. An unwavering focus on the patient mission is essential to push through.

Vivtex funded its growth and reached profitability not through traditional VC rounds, but by securing around 10 early pharma partnerships. This strategy provided significant non-dilutive revenue, reducing their reliance on investors and giving them more control over their trajectory—a powerful alternative to the typical biotech funding model.

For smaller biotechs, the key to a successful CRO relationship is treating them as a genuine partner. This requires moving beyond a transactional, fear-based dynamic to one of open communication and mutual respect. Biotechs should actively solicit CRO feedback, as they possess valuable cross-industry insights and can identify sponsor-side behaviors that need to change.

Post-IPO, credibility is a biotech's most valuable asset. Leaders should "under-promise and over-perform" by avoiding specific quarterly guidance for clinical milestones. Instead, use broader windows like "first half of the year" to build in flexibility, as clinical trials rarely run on a perfect schedule.

Vivtex's $2.1B deal with Novo Nordisk wasn't from a single pitch; it was cultivated over many years, stemming from pre-existing academic relationships. The key was building mutual scientific trust by consistently sharing progress—and even failures—allowing Novo Nordisk to observe their journey long-term.

Deep scientific knowledge is merely the entry fee for an MSL to meet with a physician. Building trust, demonstrating business acumen, and forging a genuine partnership focused on systemic patient care are the critical skills that create lasting value and justify staying in the room.